Details
Stereochemistry | UNKNOWN |
Molecular Formula | C10H12ClNO4 |
Molecular Weight | 245.66 |
Optical Activity | ( - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)OCC(O)COC1=CC=C(Cl)C=C1
InChI
InChIKey=SKPLBLUECSEIFO-UHFFFAOYSA-N
InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)
DescriptionSources: doi:10.1001/jama.1966.03100220075024Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Sources: doi:10.1001/jama.1966.03100220075024
Curator's Comment: description was created based on several sources, including:
http://www.drugs.com/mtm/chlorphenesin.html
http://www.drugbank.ca/drugs/DB00856
https://en.wikipedia.org/wiki/Chlorphenesin
Chlorphenesin carbamate (Maolate, Musil) is a centrally acting muscle relaxant used to treat muscle pain and spasms. Сhlorphenesin acts in the central nervous system (CNS) rather than directly on skeletal muscle. It also has antifungal and some antibacterial properties. The major adverse effects are drowsiness and dizziness.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: nerve impulses Sources: https://www.drugs.com/mtm/maolate.html |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: DOI:10.1001/jama.1966.03100220075024 |
Primary | MAOLATE Approved UseUnknown Launch Date1965 |
||
Curative | MAOLATE Approved UseUnknown Launch Date1965 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5133920/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: METHOCARBAMOL |
CHLORPHENESIN CARBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Sample Use Guides
for adults is 1.6 to 2.4 gm given in divided doses
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6967526
chlorphenesin carbamate (CPC) has an apparent depressing action on the spinal neuron. CPC caused marked hyperpolarizations and depressed spontaneous activities in both of the primary afferent terminals (PAT) and motoneurons (MN).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
126632-50-6
Created by
admin on Sat Dec 16 18:24:42 GMT 2023 , Edited by admin on Sat Dec 16 18:24:42 GMT 2023
|
PRIMARY | |||
|
HQC4WI89YG
Created by
admin on Sat Dec 16 18:24:42 GMT 2023 , Edited by admin on Sat Dec 16 18:24:42 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD